Clinical trial
Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy…
NCT00189969 · Bavarian Nordic, Industry · Completed
Key facts
| NCT number | NCT00189969 |
|---|---|
| Title | Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects |
| Official title | Phase I Study to Evaluate Take Rate, Immunogenicity and Safety of Bavarian Nordic's Smallpox Vaccine Elstree-BN Administered to Healthy Vaccinia-Naive Subjects in the Age of 18-32 Years |
| Lead sponsor | Bavarian Nordic, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Smallpox |
| Intervention type | Biological |
| Interventions | Elstree-BN |
| Enrollment | 50 |
| Start date | Sep 1, 2003 |
| Completion | Feb 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Apr 21, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: